Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Shares of ReNew Energy Global Plc RNW rose 4% after reporting fourth-quarter fiscal 2025 earnings of 10 cents/share, beating the Zacks Consensus Estimate of 7 cents. Shares of Northrop Grumman ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...